Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS - Disaggregation of net revenues (Details)

v3.22.2
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS - Disaggregation of net revenues (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Product revenue, net $ 18,235 $ 15,288 $ 39,031 $ 26,007
Qbrexa        
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Product revenue, net 6,111 4,568 13,487 4,568
Accutane        
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Product revenue, net 5,200 1,945 10,107 2,141
Amzeeq        
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Product revenue, net 1,265   4,731  
Targadox        
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Product revenue, net 2,756 5,727 5,390 12,926
Ximino        
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Product revenue, net 1,035 1,312 2,002 3,413
Zilxi        
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Product revenue, net 555   1,297  
Exelderm        
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Product revenue, net $ 1,313 $ 1,736 $ 2,017 2,953
Other branded products        
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Product revenue, net       $ 6